论文部分内容阅读
目的探讨胸腺肽联合抗结核药物治疗复治涂阳肺结核患者的临床效果。方法选取2013年1月至2014年2月沈阳市胸科医院就诊并接收治疗的复治涂阳肺结核患者90例为研究对象,结合患者入院时间分为观察组与对照组,各45例。对照组患者给予传统抗结核药物治疗,观察组患者在对照组治疗基础上添加胸腺肽治疗,比较两组患者的治疗效果,同时统计两组患者痰菌转阴率、肺部空洞闭合率以及不良反应发生率等疗效指标。结果观察组患者治疗总有效率明显高于对照组,且痰菌转阴率、空洞闭合率均明显高于对照组,差异均有统计学意义(均P<0.05);治疗期间,观察组患者的不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论胸腺肽联合抗结核药物治疗复治涂阳肺结核患者效果显著,能明显提升其痰菌转阴率、肺部空洞闭合率,且安全性高。
Objective To investigate the clinical effect of thymosin combined with anti-tuberculosis drugs in the treatment of retreated smear positive pulmonary tuberculosis patients. Methods From January 2013 to February 2014, 90 cases of retreatment smear positive pulmonary tuberculosis treated and treated in Shenyang Chest Hospital were enrolled in this study. The patients were divided into observation group and control group with 45 cases in each group. Patients in the control group were treated with traditional anti-tuberculosis drugs. Patients in the observation group were given thymopeptide on the basis of the control group, and the therapeutic effect was compared between the two groups. Meanwhile, the rates of sputum negative conversion rate, lung cavity closure rate and adverse reactions The incidence of other indicators of efficacy. Results The total effective rate of observation group was significantly higher than that of control group, and the sputum negative rate and void closure rate were significantly higher than those of control group (all P <0.05). During the treatment period, the observation group The incidence of adverse reactions was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Thymosin combined with anti-tuberculosis drugs in the treatment of smear-positive pulmonary tuberculosis patients with significant effect, it can significantly improve the sputum negative rate, lung cavity closure rate, and high safety.